Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

Oncogenesis is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

miR-34c-5p inhibits AREG via downregulation of the AREG-EGFR-ERK pathway. (a) The protein expression levels of the signaling components of the AREG-EGFR-ERK pathway in parental SKOV-I6 and OVS1 cells and their sphere cells are shown by western blotting. Tubulin was used as an internal control. Relative band intensity was quantified by ImageJ 1.42 and was represented with normalized mean±s.e. (N=3) below each band. (b) The protein expression levels of the signaling components of the AREG-EGFR-ERK pathway in parental SKOV-3-I6 and OVS1 cells transfected with the indicated plasmids are shown by western blotting. β-actin was used as an internal control. Relative band intensity was quantified by ImageJ 1.42 and was represented with normalized mean±s.e. (N=3) below each band. (c) The model of signaling pathway that depicts miR-34c-5p targeting AREG to inhibit the AREG-EGFR-ERK signaling and to affect ovarian cancer stemness and drug resistance.